Gain Therapeutics Future Growth

Future criteria checks 2/6

Gain Therapeutics's earnings are forecast to decline at 0.5% per annum while its annual revenue is expected to grow at 69.8% per year. EPS is expected to grow by 10.5% per annum.

Key information

-0.5%

Earnings growth rate

10.5%

EPS growth rate

Biotechs earnings growth	23.2%
Revenue growth rate	69.8%
Future return on equity	n/a
Analyst coverage	Low
Last updated	25 Apr 2024

Recent future growth updates

Recent updates

Gain Therapeutics: The Case For GCase In Parkinson's And Buyout Potential

Jan 12

Gain Therapeutics appoints CEO

Sep 20

Gain Therapeutics: Shares Of Enzyme Therapy/Neurodegeneration Specialist Look Like A Surprisingly Good Value

Oct 27

Gain Therapeutics: A True Revolution In Drug Development At Venture-Like Pricing

Aug 19

Gain Therapeutics EPS misses by $0.29

May 10

Earnings and Revenue Growth Forecasts

NasdaqGM:GANX - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	0	-39	N/A	N/A	2
12/31/2025	0	-29	N/A	N/A	4
12/31/2024	1	-22	N/A	N/A	5
12/31/2023	0	-22	-19	-19	N/A
9/30/2023	0	-22	-17	-17	N/A
6/30/2023	0	-22	-17	-16	N/A
3/31/2023	0	-19	-17	-16	N/A
12/31/2022	0	-18	-15	-15	N/A
9/30/2022	0	-16	-15	-15	N/A
6/30/2022	0	-16	-14	-14	N/A
3/31/2022	0	-15	-12	-12	N/A
12/31/2021	0	-14	-12	-12	N/A
9/30/2021	0	-12	-10	-10	N/A
6/30/2021	0	-8	-8	-8	N/A
3/31/2021	N/A	-5	-5	-5	N/A
12/31/2020	N/A	-4	-3	-3	N/A
9/30/2020	N/A	-3	-2	-2	N/A
12/31/2019	N/A	-2	-2	-2	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: GANX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: GANX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: GANX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: GANX's revenue (69.8% per year) is forecast to grow faster than the US market (8.2% per year).

High Growth Revenue: GANX's revenue (69.8% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if GANX's Return on Equity is forecast to be high in 3 years time

Gain Therapeutics Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Consensus revenue estimates fall by 40%

Consensus revenue estimates decrease by 11%, EPS upgraded

Consensus revenue estimates fall by 16%

Consensus revenue estimates increase by 193%, EPS downgraded

Consensus revenue estimates increase by 17%

Consensus revenue estimates increase by 24%

Recent updates

Gain Therapeutics, Inc., Annual General Meeting, Jun 24, 2024

Consensus revenue estimates fall by 40%

Gain Therapeutics, Inc. Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287

Gain Therapeutics, Inc. Appoints Gene Mack as Chief Financial Officer

Independent Director recently bought US$116k worth of stock

Gain Therapeutics, Inc. Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer

New major risk - Financial position

Gain Therapeutics, Inc. Announces Xavi Barril Leaves as Chief Technology Officer

Gain Therapeutics: The Case For GCase In Parkinson's And Buyout Potential

Consensus revenue estimates decrease by 11%, EPS upgraded

Gain Therapeutics, Inc. Announces Preclinical Data Showing Restoration of Enzymatic Function with Novel Allosteric Regulators in GM1 Gangliosidosis Model

Gain Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $6.65573 million.

Gain Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $6.65573 million.

Gain Therapeutics, Inc. has filed a Follow-on Equity Offering.

Gain Therapeutics Announces Dosing of First Two Subjects in Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease

Gain Therapeutics Presents New Preclinical Data Demonstrating A Reduction of Plasma Neurodegeneration Biomarker NfL After Administration of Its Drug Candidate GT-02287 in GBA1 Parkinson's Disease Model

Consensus revenue estimates fall by 16%

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: US$0.62 loss per share (vs US$0.43 loss in 2Q 2022)

Consensus revenue estimates increase by 193%, EPS downgraded

Consensus revenue estimates increase by 17%

Gain Therapeutics, Inc. Announces Executive Changes

Consensus revenue estimates increase by 24%

High number of new and inexperienced directors

Gain Therapeutics, Inc. Presents New Preclinical Data Showing Promising Pharmacological Activity in Parkinson's Disease Patient-Derived Dopaminergic Neurons

Gain Therapeutics Announces Chief Executive Officer Changes

Gain Therapeutics appoints CEO

Gain Therapeutics, Inc. Presents New Preclinical Data Demonstrating Potential Disease Modifying Benefits of Its Novel Brain Penetrant Small Molecule Candidate GT-02287 in Two Preclinical Models of Parkinson's Disease

Price target decreased to US$19.25

Consensus forecasts updated

Consensus forecasts updated

Gain Therapeutics, Inc., Annual General Meeting, Jun 16, 2022

Price target decreased to US$22.00

High number of new and inexperienced directors

Price target decreased to US$22.00

Gain Therapeutics Presents Additional Confirmatory Data on its Gaucher Disease Program at the 2022 Glycolipid

Gain Therapeutics Presents Preclinical Data on Its Structurally Targeted Allosteric Regulators in Gba1 Gaucher Disease At the Worldsymposium 2022

Gain Therapeutics: Shares Of Enzyme Therapy/Neurodegeneration Specialist Look Like A Surprisingly Good Value

Gain Therapeutics, Inc. Announces Positive Topline Data in Patient-Derived Ipsc Study Evaluating Star Compounds as A Treatment for Gaucher and Parkinson’S Disease

Gain Therapeutics: A True Revolution In Drug Development At Venture-Like Pricing

Gain Therapeutics EPS misses by $0.29

Gain Therapeutics, Inc. Presents Positive In Vitro & In Vivo Data on Its Orally Bioavailable Brain Penetrant Star Compounds for the Treatment of GBA1 Parkinson’s Disease & Related a-synucleopathies at the XXVI IAPRD World Congress

Gain Therapeutics, Inc. has completed an IPO in the amount of $40.000004 million.

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies